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Vertical transmission is possible in pregnant women with SARS-CoV-2 infection, and a shorter 56 
interval between symptoms to delivery is associated with mother-to-child transmission.  57 




Objective: To evaluate the potential for and risk factors of SARS-CoV-2 vertical transmission. 60 
Methods: A cohort of pregnant women with confirmed coronavirus disease 2019 (COVID-19) 61 
diagnosis (positive swab and/or serology) in whom reverse transcription-polymerase chain 62 
reaction (RT-PCR) for SARS-CoV-2 was performed at delivery using maternal serum and at 63 
least one of the following biological samples: cord blood (CB), amniotic fluid (AF) or 64 
colostrum and/or oropharyngeal swab (OPS) of the neonate, with the samples being collected 65 
at 48 hours after birth. The association of maternal and obstetrics parameters with maternal 66 
blood positivity and AF and/or CB at delivery and the influence of SARS-CoV-2 positivity in 67 
AF and/or CB on neonatal outcomes were investigated.  68 
Results: A total of 109 pregnant women were included. Positive RT-PCR for SARS-CoV-2 69 
was observed in 14·7% (16/109) of maternal blood samples, 13·9% (6/43) of AF samples, 70 
6·7% (7/105) of CB samples, 2·1% (2/97) of colostrum samples and 3.7% (2/54) of neonatal 71 
OPS samples. The duration of the interval between COVID-19 symptoms and delivery was 72 
inversely associated with SARS-CoV-2 positivity in the maternal blood (p= 0·002) and in the 73 
AF and/or CB (p= 0·049). Moreover, there was an association between SARS-CoV-2 positivity 74 
in maternal blood and SARS-CoV-2 positivity in AF and/or CB (p= 0·001). In turn, SARS-75 
CoV-2 positivity in AF and/or CB was associated with OPS positivity in neonates (p= 0·020). 76 
Conclusion: The findings support that vertical transmission can occur in pregnant women with 77 
COVID-19 and that a shorter interval between maternal symptoms and delivery is an 78 
influencing factor.  79 
 80 
Introduction 81 
Although the burden of COVID-19 for individuals with particular conditions, such as 82 
chronic diseases, has been described to some extent1, the impact of disease and/or the virus on 83 
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pregnant women and their offspring is not very well documented. In addition, it is not well 84 
known whether the disease at an acute stage or severe disease around the time of delivery have 85 
different impacts on pregnancy outcomes and vertical transmission.2-9  86 
Several recent reports of vertical transmission have been published, mostly based on 87 
case reports, case series, or meta-analysis and reviews of such series. Conversely, few studies 88 
have systematically investigated the presence of SARS-COV-2 in biological samples such as 89 
cord blood (CB), placental tissue, and amniotic fluid (AF) to support the role of vertical 90 
transmission.5,8,10-13 Moreover, the results of these reports14-17 have been inconsistent, which 91 
may be due to the timing of sample collection (during the acute or post-recovery phase of 92 
maternal COVID-19), type of assays used to detect the presence of the virus, and lack of test 93 
accuracy.18-19  94 
Given the lack of data on the potential of, timing, circumstances and risk factors 95 
influencing vertical transmission of SARS-CoV-2, we conducted a prospective cohort study of 96 
pregnant women with COVID-19 at different stages of pregnancy using systematic collection 97 
of samples (maternal blood, CB, AF and colostrum) obtained at delivery reflecting potential 98 
exposure to maternal infection and in the neonate to ascertain infection. Similar to infection 99 
with other viruses, a deeper understanding of the mechanisms and timing of SARS-CoV-2 100 
transmission during pregnancy will allow the development of better prevention and 101 
management strategies among pregnant women. 102 
 103 
Material and Methods 104 
This analysis of vertical transmission is one of the aims of a major cohort study, 105 
“exploratory study on COVID-19 in pregnant women,” which began on April 12th at Hospital 106 
das Clinicas (HC-FMUSP) and Hospital Universitario (HU-USP), Sao Paulo University and is 107 
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ongoing. The exploratory study also included estimating the seroprevalence of SARS-CoV-2 108 
at delivery at HU.  109 
When the COVID-19 pandemic started in Sao Paulo, our institution organized the 110 
Hospital das Clinicas (HC) as a COVID-19 hospital and the Hospital Universitario (HU) as a 111 
non-COVID-19 hospital. Therefore, pregnant women with COVID-19 or flu symptoms or 112 
contact with a SARS-CoV-2-positive person would be seen at HC; others would be seen at HU. 113 
In addition, at HU, a triage system at the hospital entrance was established; pregnant women 114 
with COVID-19 or flu symptoms or contact with a SARS-CoV-2-positive person were referred 115 
immediately to HC at any time during pregnancy, delivery or puerperium. Patients seen at HC 116 
were only allowed to follow the antenatal or puerperium at HU after 14 days of quarantine and 117 
without symptoms. 118 
 For the present investigation, pregnant women who fulfilled the following inclusion 119 
criteria were selected: 1) singleton pregnancies with live fetuses with a diagnosis of COVID-120 
19 during pregnancy or at delivery by RT-PCR using a nasopharyngeal swab (NPS) or 121 
serology; 2) COVID-19 or flu-like symptoms during pregnancy or at delivery; and 3) 122 
investigation of SARS-CoV-2 by RT-PCR using maternal blood and at least one biological 123 
sample at delivery (CB, AF) or after birth (colostrum or oropharyngeal swab (OPS) from the 124 
neonate). 125 
 All pregnant women admitted to HC were investigated for SARS-CoV-2 infection by 126 
molecular testing (RT-PCR) using samples collected from the respiratory tract (nasopharynx 127 
and/or trachea) from the 3rd day of symptoms. In cases with negative results, NPS testing was 128 
repeated, or SARS-CoV-2 serology was performed after the 8th day of symptoms. The 129 
following symptoms were considered COVID-19 symptoms: fever or chills, cough, dyspnea, 130 
fatigue, myalgia, sore throat, headache, congestion, or runny nose; loss of taste or smell; 131 
diarrhea. In addition, any flu-like symptoms were considered COVID-19 symptoms until 132 
proven otherwise. 133 
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At HC, pregnant women with flu symptoms were evaluated by our clinical staff and 134 
hospitalized if they presented any of the following situations: (i) need for clinical support or 135 
(ii) other obstetric emergencies such as hypertensive disorders, labor, premature rupture of 136 
membranes or fetal distress. Severe COVID-19 cases were defined as those who needed 137 
supplemental oxygen (because of dyspnea, respiratory frequency ≥24 breaths per minute; 138 
and/or oxygen saturation level <95%) or required admission to the intensive care unit. Delivery 139 
was indicated based on obstetrics and/or maternal clinical worsening in cases of severe 140 
COVID-19. The mode of delivery was chosen according to obstetrics and maternal clinical 141 
conditions. To avoid contamination of the neonate, delayed cord clamping and skin-to-skin 142 
contact were not allowed in cases of delivery at HC. In addition, neonates were separated from 143 
their mothers and other family members, and breastfeeding was not allowed until hospital 144 
discharge. 145 
Information on patient demographics and history as well as details of treatments and 146 
results from exams were recorded in a REDCap platform database.  147 
The following samples were obtained at delivery from pregnant women with symptoms 148 
of COVID-19 during pregnancy or at delivery: maternal blood, CB, AF, and the placenta. 149 
Maternal blood samples were collected through venipuncture immediately before delivery. 150 
Cord artery or vein blood samples (5 to 10 mL) were collected by needle puncture after cord 151 
clamping. The serum and plasma were separated and aliquoted. AF was collected before the 152 
rupture of amniotic membranes via direct needle aspiration using a 20-mL syringe. Within 48 153 
hours of delivery, a research staff member collected a 5-mL colostrum sample into a sterile 154 
tube after appropriate cleaning of the nipples and breasts. All samples were stored at -80°C 155 
until analysis. 156 
For neonates born at HC, a swab was collected from the oropharynx and trachea (if the 157 
newborn was intubated), or two samples from the oropharynx were collected at 48 hours after 158 
delivery for SARS-CoV-2 RT-PCR analysis. In cases of any positive test for the neonate, an 159 
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additional sample was obtained at 72 hours after delivery and tested to exclude false-positive 160 
results. Neonates born at HU were not subjected to SARS-CoV-2 investigation, as the mothers 161 
were not in the acute phase of the disease, and breastfeeding was allowed. 162 
Laboratory methods 163 
Nucleic acid was extracted from 140 µL of clinical samples using a QIAmp Viral RNA 164 
mini kit (Qiagen, Germany), eluted in 60 µL and stored at -80°C until processing. Detection of 165 
viral RNA was performed using a qualitative RT-PCR - RealStar SARS-CoV-2 RT-PCR kit 166 
1.0 RUO (Altona Diagnostic, Germany) according to the manufacturer's instructions. The 167 
reaction targets the β-coronavirus E gene and SARS-CoV-2 S gene. The assay was performed 168 
using a LightCycler 96 Instrument (Roche, Germany). 169 
Samples were considered positive when the cycle threshold (Ct) value was ≤40 for at 170 
least one of the targets. The assay was evaluated with an independent validation by Visseaux 171 
et al.20, showing high sensitivity and specificity comparable with protocols currently 172 
recommended by the Health Organization (WHO). 173 
A serological test (IgG/IgM antibodies) was performed using the Wondfo One Step 174 
COVID-19 test (Guangzhou Wondfo Biotech, China). The test was performed using 10μL of 175 
serum pipetted into the sample cavity of the test device, after which 80μL was added to the 176 
cavity below the sample cavity. The result was read in 15 minutes by three people that had 177 
received appropriate training. The color change was compared to the assay standard.21  178 
For viral culture, Vero cells (ATCC CCL-81) were used as previously described.22-24 179 
Vero CCL81 cells were cultured in Dulbecco minimal essential medium supplemented with 180 
heat-inactivated fetal bovine serum (10%) and antibiotics/antimycotics (Cultilab, Campinas, 181 
Brazil). 182 
For virus isolation, samples were inoculated in Vero cell culture in plastic bottles (jet 183 
biofilm, 12.5cm2 area, 25mL capacity) immediately after processing. The inoculated cultures 184 
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were grown in a 37°C incubator in an atmosphere of 5% CO2. The cell cultures were maintained 185 
for at least two weeks and observed daily for evidence of the cytopathic effect. 186 
At least two subcultures were performed weekly. Presumptive detection of virus in 187 
supernatants showing cytopathic effect was investigated using an inverted microscope (Nikon, 188 
Japan) and confirmed by specific RT-PCR as described above. 189 
Quantitative continuous variables are presented as means and standard deviations (SD) 190 
or medians and minimum and maximum values. Categorical variables are presented as absolute 191 
frequencies and percentages. Comparison between groups was performed using Fisher's exact 192 
test for unpaired samples with normal distribution; when the distribution was not normal, the 193 
Mann-Whitney U nonparametric test was employed. Differences were considered significant 194 
when the p-value was less than 0.05. The data were analyzed using Statistical Package for the 195 
Social Sciences (SPSS version 20 IBM, Armonk, NY, USA). 196 
The study protocol was approved by the ethics committees of both hospitals (CAAE: 197 
30270820.3.0000.0068) and was registered at ClinicalTrial.gov (NCT04647994). All 198 
participants provided informed consent before participating in the study. 199 
 200 
Results 201 
Between 12th April and 30th September, 1044 pregnant women were admitted at HC and HU, 202 
and 595 pregnant women being assessed; 109 fulfilled the inclusion criteria for the present 203 
analysis (Figure 1). Details regarding the demographics, obstetrics and clinical characteristics 204 
of the participants are presented in Table 1. For 108 cases, the median interval between 205 
COVID-19 symptoms and delivery was 23·5 days (7·2-76·2). In one case, the patient 206 
experienced COVID-19 symptoms during pregnancy but was not able to provide the timing; 207 
therefore, this case was not included in the analysis. The majority of patients (80/109, 73·4%) 208 
were admitted to the hospital due to COVID-19, and 36·7% (40/109) had severe disease. 209 
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Rates of RT-PCR positivity for SARS-CoV-2 in biological samples collected at 210 
delivery were 14·7% (16/109) for maternal blood, 13·9% (6/43) for AF and 6·7% (7/105) for 211 
CB. Overall, there were some difficulties regarding the collection of AF due to the severity of 212 
some cases and the need to ascertain that the samples were not contaminated with maternal 213 
fluids during delivery, which contributed to the small number of AF samples collected. In total, 214 
2·1% (2/97) of the maternal colostrum samples were positive for SARS-CoV-2 by RT-PCR. 215 
Viral culture was performed in these two positive cases and did not show viral replication, 216 
which may be due to the high fat composition of colostrum, which can render this analysis 217 
difficult. 218 
Distributions of SARS-CoV-2 status in the investigated compartments are presented in 219 
Table 2. Details of the cases with at least one positive sample for SARS-CoV-2 are described 220 
in Table 3. 221 
All pregnant women with positive SARS-CoV-2 RT-PCR results for maternal blood at 222 
delivery presented COVID-19 symptoms in the third trimester, with a significant difference 223 
(p= 0·007; Table 4). In addition, a significantly shorter interval between the occurrence of 224 
COVID-19 symptoms and delivery (7·5vs 29 days, p= 0·002) was observed in cases of SARS-225 
CoV-2 positivity in blood, and this result was also observed when considering intervals ≤ 10 226 
or > 10 days (p= 0·006; Table 4). Conversely, no influence of other maternal, COVID-19-227 
related, or obstetric factors was observed (Table 4). 228 
Table 5 provides the associations of maternal COVID-19 and obstetrics parameters 229 
with SARS-CoV-2 RT-PCR positivity in AF and/or CB at delivery. The interval between the 230 
onset of COVID-19 symptoms and delivery was associated with positive SARS-CoV-2 RT-231 
PCR results in AF and/or CB at delivery (7 vs 27 days, p= 0·049), which was also observed for 232 
intervals ≤ 10 or > 10 days (p= 0·032; Table 5). In addition, SARS-CoV-2 RT-PCR positivity 233 
in maternal serum at delivery was associated with SARS-CoV-2 RT-PCR positivity in AF 234 
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and/or CB (54·5% vs 10·2%; p= 0·001). There was no influence observed for other maternal, 235 
COVID-19-related, or obstetric factors. 236 
To investigate whether a positive SARS-CoV-2 RT-PCR result in AF and/or CB 237 
influences neonatal outcome, we analyzed the association between neonatal parameters and 238 
positive and negative SARS-CoV-2 AF and/or CB among the 54 neonates tested for SARS-239 
CoV-2 using OPS (Table 6). SARS-CoV-2 positivity in AF and/or CB was only associated 240 
with OPS positivity in the neonate (2 vs 0; p= 0·020). 241 
In two neonates (3·7%; 2/54), OPS was positive for SARS-CoV-2, suggesting vertical 242 
transmission. These two cases represent 25% (2/8) of the AF and/or CB samples positive for 243 
SARS-CoV-2 among the cases for which OPS was examined for SARS-CoV-2 (n= 54). For 244 
the two cases with suspected vertical transmission, SARS-CoV-2 was identified in three 245 
compartments, but not in the colostrum, for one; for the other case, the CB and colostrum 246 
samples were positive for SARS-CoV-2 (Table 3). 247 
The two neonates with suspected vertical transmission (Table 3) were born at HC and 248 
had the following outcomes. The first was a female delivered by caesarean section at 33·57 249 
weeks of gestation due to worsening of the maternal COVID-19 condition. The five-minute 250 
Apgar score was 9, and the birth weight was 2130 grams. OPS samples collected at 48 hours 251 
of life and repeated at 72 hours were positive for SARS-CoV-2. RT-PCR for SARS-CoV-2 252 
was also evaluated on the 17th day of life and was positive, becoming negative on the 22nd day 253 
after delivery. Serology performed on the 23rd of life showed IgG positivity. On the 3rd day, the 254 
neonate presented decreased oxygen pulse saturation requiring oxygen inhalation until the 14th 255 
day of life. The lungs were normal on chest X-ray carried out on the 5th day of life; however, 256 
lung ultrasound revealed the presence of coalescent B-lines and subpleural consolidations on 257 
the base of the left posterior lung. Additionally, chest computerized tomography (CT) scan 258 
showed opacities and atelectasis in the right upper lobe and a slightly diffuse increase in the 259 
attenuation of the lung parenchyma. Her blood cell counts were normal. Within 22 days, the 260 
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infant presented enterorrhagia requiring blood transfusion. The infant was discharged from the 261 
hospital on the 26th day of life. The newborn was fed formula until the day of hospital discharge. 262 
The second case of positive neonatal OPS was a male born at 38·57 weeks by vaginal 263 
delivery with spontaneous labor and rupture of the membranes two hours before birth. The 264 
five-minute Apgar score was 9, and the birth weight was 2980 grams. The SARS-CoV-2 RT-265 
PCR result using OPS collected on the second day of life was positive, and the test was repeated 266 
at 72 hours of life, with a positive result. On the 7th day of life, before hospital discharge, OPS 267 
testing was repeated, and the result was negative. During the hospital stay, the blood cell count 268 
and lung ultrasonography were normal. On his 3rd day, the neonate presented asymptomatic 269 
sinus bradycardia associated with hypocalcemia. After three days of enteral calcium infusion 270 
the heart rate and serum calcium levels were normal. The newborn was fed with formula until 271 
hospital discharge at 8 days of life. 272 
 273 
Discussion 274 
The findings of this prospective study conducted in a single center over a six-month 275 
period demonstrated the following. First, vertical transmission of SARS-CoV-2 from a mother 276 
with COVID-19 during pregnancy to their baby is possible. Second, SARS-CoV-2 can be 277 
recovered in all maternal biological compartments that may expose the neonate (AF, CB and 278 
colostrum). Third, recent infection in the mother is associated with positivity for SARS-CoV-279 
2 in maternal blood and in the AF and/or CB compartments. Fourth, the presence of SARS-280 
CoV-2 RT-PCR positivity in maternal blood at delivery is related to SARS-CoV-2 RT-PCR 281 
positivity in AF and/or CB, which in turn influences the finding of SARS-CoV-2 positivity in 282 
the neonate. 283 
The possibility of vertical transmission of SARS-CoV-2 during pregnancy has been 284 
described previously.10 In our study, 3.7% of the neonates tested had positive OPS RT-PCR 285 
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results for SARS-CoV-2, similar to findings described in a recent meta-analysis11 involving 286 
936 neonates (3.2%). However, we observed higher rates of SARS-CoV-2 RT-PCR positivity 287 
for AF (13.9% vs 0%) and CB (6.7% vs 2.9%) than reported in this previous meta-analysis. 288 
Interestingly, RT-PCR positivity was detected for some AF and/or CB samples, with a 289 
more than four-week interval between maternal symptoms and delivery. Nonetheless, the 290 
prolonged presence of the virus is unusual and does not mean that the virus is able to replicate 291 
and cause infection. To clarify this issue, it is necessary to cultivate the virus to determine viral 292 
replication in these samples. 293 
In our sample, we observed SARS-CoV-2 RT-PCR positivity in 2.1% of colostrum 294 
samples. In one case, CB was also positive, though none of the other tested compartments was 295 
positive in the other case. Viral cultures were negative for these two cases, suggesting that 296 
SARS-CoV-2 RNA may not represent replication-competent virus in the colostrum. As 297 
demonstrated in our study, previous research has also reported 1/18 positive cases of SARS-298 
CoV-2 in the colostrum and maternal milk,25 and another recent study found one case (1/11) of 299 
SARS-CoV-2 positivity in maternal milk collected on the 5th day after delivery.10 300 
Our finding that the interval between COVID-19 symptoms and delivery influences the 301 
detection of SARS-CoV-2 in AF and CB, in turn increasing potential exposure of the fetus and 302 
neonate, has major clinical implications. These implications include (i) the need to reinforce 303 
personal protection for pregnant women mainly in the third trimester of pregnancy; (ii) 304 
whenever possible, delivery should be avoided during the acute phase of COVID-19 infection; 305 
and (iii) molecular tests (OPS or serum RT-PCR) to evaluate the possibility of SARS-CoV-2 306 




Despite our finding of SARS-CoV-2 positivity in colostrum samples, it is not possible 309 
to assume that mother-to-infant transmission occurs by breastfeeding, and further studies with 310 
larger samples are needed. 311 
 All but one case of maternal sample positivity occurred among pregnant women who 312 
developed COVID-19 in the third trimester. The two neonates with positive OPS samples 313 
presented mild symptoms after delivery. It seems that SARS-COV-2 can present similar 314 
characteristics to other pathogens, such as cytomegalovirus and toxoplasma, whereby 315 
transplacental passage tends to increase with gestational age but with lower fetal/neonatal 316 
compromise.26 Nevertheless, our study only included three women with COVID-19 in the first 317 
trimester. Further cohort studies including pregnant women who have acquired SARS-CoV-2 318 
at earlier stages of pregnancy are required to evaluate the true effects of infection by this virus 319 
on vertical transmission. 320 
The major strength of this study is that we evaluated a systematic collection of samples 321 
that represents exposure of the neonate. Indeed, in the two neonates with positive OPS samples, 322 
at least two of the compartments were positive, reinforcing the hypothesis of intrautero 323 
transmission. 324 
The main limitation of the study is that we did not more fully ascertain the infection 325 
status of the neonates by testing their serum for SARS-CoV-2 by RT PCR or performing IgM 326 
serology, which may have provided additional cases of vertical transmission, as it is known 327 
that NPS/OPS may lack sensitivity and that a positive result may be secondary to intrapartum 328 
contamination.18 At this stage of the epidemic, the optimal test to determine infection status in 329 
the neonate remains unclear.27 We acknowledge that a wider panel evaluation of multiple 330 
biological sites may have increased the sensitivity of viral detection. 331 
In conclusion, our study confirms the possibility of vertical transmission of SARS-332 
CoV-2 from infected symptomatic mothers to their infants, particularly if infection occurs close 333 
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to delivery. Therefore, our data suggest that special care is needed in pregnant women with 334 
COVID-19 in the third trimester and that whenever possible, delivery in the acute phase of the 335 
disease should be avoided. 336 
 337 
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Table 1. Study population demographic, clinical, obstetrical, and neonatal characteristics. 448 
 449 
CHARACTERISTICS N= 109 
n (%), mean (SD), median (range) 
  Maternal age, years 29.5 (7.3) 
  Body mass index (n= 107) 30.5 (18.7-48.3) 
  Smoking habit 10 (9.2) 
PREPREGNANCY MORBIDITY 
  Hypertension 14 (12.8) 
  Diabetes 4 (3.7) 
  Other* 31 (28.4) 
OBSTETRICS HISTORY  
  Nulliparous 35 (32.1) 
  Preeclampsia 10 (9.2) 
  Gestational diabetes 21 (19.3) 
MATERNAL COVID-19/SARS-CoV-2 PARAMETERS 
  Diagnosis by RT-PCR NPS 79 (72.5) 
  Diagnosis by serology 30 (27.5) 
  Gestational age at COVID-19 symptoms, weeks (N= 108) 31.2 (5-40.6) 
  Interval between symptoms and delivery, days (N= 108) 23.5 (2-242) 
  Hospital admission due to COVID-19 80 (73.4) 
  Length of hospital stay, days (N= 80) 7 (3-12) 
  Required oxygen supply 38 (34.9) 
  ICU due to COVID-19 25 (22.9) 
  Severe COVID-19 40 (36.7) 
DELIVERY PARAMETERS 
 Gestational age at delivery, weeks 37.9 (27.1-41.1) 
 Caesarean section 79 (72.5) 
 Length of hospital stay after delivery, days 3 (1-86) 
NEONATE PARAMETERS 
 Birth weight, grams 3040 (680-3040) 
 Apgar score at 5 minutes <7 10 (9.2) 
 ICU admission 34 (31.2) 
 Required mechanical ventilation 10 (9.2) 
 Length of hospital stay, days 4 (2-190) 
 Breastfeeding during hospital stay 50 (45.9) 
 Neonatal death 0 
*Other: cardiac disease, lung disease, hypothyroidism, anemia, neurological disorders. Severe COVID-19: 450 
required oxygen supply or ICU admission. ICU: intensive care unit; NPS: nasopharyngeal swab; SD: standard 451 










Table 2. Distribution of SARS-CoV-2 PCR status in compartments (maternal blood, amniotic fluid, 460 






Cord blood Amniotic Fluid Colostrum Neonate 
1 + + + - + 
1 - + - + + 
2 + + NA - - 
2 - + NA - - 
1 - + + - NA 
1 + - + - - 
1 + - + NA - 
2 + NA 1 (+),1(-) - - 
1 - - + - NA 
1 - - NA + - 
5 + - NA - 3 (-), 2 (NA) 
2 + - NA NA 1 (-), 1 (NA) 
2 + - - - - 
39 - - 9 (-), 30 (NA) - NA 
34 - - 16 (-), 18 (NA) - - 
5 - - - NA NA 
2 - - - NA - 
2 - - NA NA NA 
2 - - NA NA NA 
1 - - NA NA - 
1 - NA - - - 
1 - NA NA - NA 





































2 Swab Mild 38.14 38.57 Neg Ct 21.43 
Gene E; Ct 
20.53 Gene 
S 






3 Swab Mild 38.43 39.43 Neg Ct 30.22, 
Gene E 
NA Neg  
Neg 
4 Swab Mild 29 38.43 Neg Ct 36.87 














Gene E; Ct 
25.46 Gene 
S 
NA Neg  
Neg 
6 Swab Severe 25.57 39.14 Neg Ct 37.75 
Gene E 
NA Neg  
NA 




NA Neg  
Neg 
8 Swab Severe 34 35.14 Ct 37.43, 
Gene E 









10 Swab Mild 37.71 38 Ct 36.24, 
Gene E 






11 Swab Mild 39.28 40 Ct 37.52, 
Gene E 














13 Swab Severe 30.71 31.71 Ct 34.42 
Gene E 
Neg Neg Neg  
Neg 
14 Swab Mild 38.86 40.28 Ct 37.00, 
Gene E 
Neg Neg Neg  
Neg 
15 Swab Severe 33.86 35.43 Ct 34.85, 
Gene E 
NA Neg Neg  
Neg 
16 Swab Mild 39.28 39.85 Ct 34.02, 
Gene E 
Neg NA Neg  
Neg 






Neg NA Neg  
Neg 




Neg NA Neg  
Neg 
19 Swab Severe 37.57 37.86 Ct 33.36, 
Gene E 
Neg NA NA  
Neg 
20 Swab Mild 28.86 37.71 Ct 35.06 
Gene E 
Neg NP NA  
NA 
21 Serol Mild 28 39.86 Ct 35.61, 
Gene E 
Neg NA Neg  
NA 
22 Serol Mild 34.28 36.71 Ct 36.85 
Gene E 
Neg NA Neg  
NA 
Ct: cycle threshold; Diag: diagnosis method; Serol: serology; GA_S: gestational age at symptoms; GA_D: 468 
gestational age at delivery; Neg: negative; Pos: positive; NA: not available 469 
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Table 4. Association of maternal COVID-19 status and obstetrics parameters with positive maternal 470 
blood RT-PCR for SARS-CoV-2 at delivery (N= 109). 471 
 472 
Parameters 
          Maternal blood 
p 
Positive SARS-CoV-
2   RT-PCR (N= 16) 
Negative SARS-CoV-
2  RT-PCR (N= 93) 
COVID-19 Symptoms by pregnancy trimester (N=108) 
      First 0 (0) 3 (3.3) 
0.007*       Second 0 (0) 31(33.7) 
      Third 16 (100) 58 (63) 
Hospital admission due to COVID-
19 
14 (87.5) 66 (71) 0.23* 
Severe COVID-19 7 (43.8) 33 (35.5) 0.58* 
Interval COVID-19 symptoms to 
delivery, days (N=108) 
7.5 (2-83) 29 (2-242) 0.002† 
Interval COVID-19 symptoms to delivery (N=108) 
   ≤ 10 days 10 (62.5) 23 (25) 
0.006* 
   > 10 days 6 (37.5) 69 (75) 
Caesarean section  13 (81.3) 66 (71) 0.55* 
Gestational age at delivery, weeks 37.2 (31.7-40.3) 38.3 (27.1-41.1) 0.38† 
BMI (N=107) 29·7 (20.9-43.7) 30.5 (18.7-48.3) 0.56† 
Prepregnancy morbidity 
  Hypertension 0 (0) 14 (15.1) 0.22* 
  Diabetes 2 (12.5) 2 (2.2) 0.10* 
  Other 5 (31.3) 26 (28) 0.77* 
Obstetric complications 
 Preeclampsia 0 (0) 10 (10.8) 0.35* 
 Gestational diabetes             4 (25) 17 (18.3) 0.51* 
Data are presented as the number (percentage) and median (range). 473 
Severe COVID-19: required oxygen supply or ICU admission. BMI: body mass index; Other: cardiac disease, 474 
lung disease; hypothyroidism; anemia, neurological disorders. 475 












Table 5. Association of maternal COVID-19 and obstetrics parameters with positive RT-PCR 486 





Positive SARS-CoV-2  
RT-PCR (N= 11) 
Negative SARS-CoV-2 
RT-PCR (N= 98) 
COVID-19 symptoms by pregnancy trimester (N= 108) 
      First 0 (0) 3(3.1) 
0.33* 
      Second 1(9.1) 30 (30.9) 
      Third 10 (90.9) 64 (66)  
Hospital admission due to COVID-19 10 (90.9) 70 (71.4) 0.28* 
Severe COVID-19 5 (45.5) 35 (35.7) 0.53* 
Interval COVID-19 symptoms to delivery, 
days (N= 108) 
7 (2-95) 27 (2-242) 
0.049
† 
Interval COVID-19 symptoms to delivery (N= 108) 
   ≤ 10 days 7 (63.6) 26 (26.8) 0.032
*    > 10 days 4 (36.4) 71 (73.2) 
Positive SARS-CoV-2 RT-PCR for the 
maternal blood at delivery 
6 (54.5) 10 (10.2) 
0.001
* 
Caesarean section  9 (81.8) 70 (71.4) 0.72* 
Gestational age at delivery, weeks 38.6 (33.6-40) 37.8 (27.1-41.1) 0.72† 
BMI (N= 107) 29.4 (23.1-46.2) 30.6 (18.7-48.3) 0.47† 
Prepregnancy diseases 
  Hypertension 0 (0) 14 (14.3) 0.35* 
  Diabetes 1 (9.1) 3 (3.1) 0.35* 
  Other* 3 (27.3) 28 (28.6) 1.00* 
Obstetric complications 
  Preeclampsia 1 (9.1) 9 (9.2) 1.00* 
  Gestational diabetes 1 (9.1) 20 (20.4) 0.69* 
Data presented as the number (percentage); median (range). 489 
Severe COVID-19: required oxygen supply or ICU admission; BMI: body mass index; Other: cardiac disease, lung disease; 490 
hypothyroidism; anemia, neurological disorders. 491 









Table 6. Association of neonatal parameters according to SARS-CoV-2 RT-PCR positivity in 499 
compartments (amniotic fluid and/or cord blood) in cases in which the neonates were tested for 500 





   p Positive SARS-CoV-2       
RT-PCR (n= 8) 
Negative SARS-CoV-2 
 RT-PCR (n= 46) 
Swab positivity for SARS-CoV-2  2 (25) 0 (0) 0.02* 
Gestational age at delivery, weeks 38.3 (33.6-40) 35.6 (27.1-41.1) 0.20† 
Sex  
   Female 3 (37.5) 22 (47.8) 
0.71* 
   Male 5 (62.5) 24 (52.2) 
Birth weight 3080 (1732-3490) 2490 (680.3870) 0.22† 
Apgar score at 5 minutes < 7 1 (12.5) 8 (17.4) 1.00* 
ICU admission 2 (25) 26 (56.5) 0.13* 
Length of hospital stay, days 5.5 (2-29) 6 (2-190) 0.39† 
Requiring mechanical ventilation 0 (0) 10 (21.7) 0.33* 
Data are presented as the number (percentage) and median (range). 503 
ICU: intensive care unit * Fisher exact test; † Mann-Whitney test. 504 
  505 
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Figure legend: Flow-chart of the study population. HU: Hospital Universitario, HC: 506 
Hospital das Clinicas. 507 
